CVRX — CVRx, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1235912 ·
Last close
$6.08
Market Cap
$161.34M
52W High
$9.84
52W Low
$5.00
ADV30
351,515
Next earnings
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 14,769,000 12,881,000 -12,161,000 -13,120,000 99,728,000 72,303,000 70,619,000
Dec 2025 16,024,000 13,825,000 -11,184,000 -11,934,000 104,794,000 75,708,000 65,470,000
Sep 2025 14,690,000 12,753,000 -12,268,000 -12,870,000 111,325,000 85,124,000 63,271,000
Jun 2025 13,589,000 11,450,000 -14,376,000 -14,736,000 119,564,000 95,025,000 61,630,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-40,170,000
Investing CF
$-580,000
Financing CF
$10,520,000
CapEx
$-580,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.05
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-590,652,000
Inventory
$12,205,000
Receivables
$10,665,000
ST Investments
EBIT TTM
$-47,497,000
Pretax Income TTM
$-53,324,000
Interest Exp TTM
$5,827,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$59,072,000
EBITDA
$-49,212,000
Free Cash Flow
$-23,050,750
Enterprise Value
$148,430,544
Total Cash
$72,303,000
Total Debt
$59,395,000
Shares Out
26,535,944
Trailing EPS
$-2.01
Book Value
$1.10
ROE
-107.0%
ROA
-27.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 56,651,000 -51,265,000 -53,306,000 104,794,000 65,470,000 -40,170,000
Dec 2024 51,292,000 -59,490,000 -59,965,000 133,414,000 62,359,000 -39,144,000
Dec 2023 39,295,000 -43,103,000 -41,199,000 115,229,000 39,282,000 -39,021,000
Dec 2022 22,469,000 -42,527,000 -41,428,000 124,937,000 15,757,000 -42,677,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.89

Peers — same industry

TickerNameMarket CapLastDaily %
EDAP EDAP TMS SA $161.55M $4.31
EBRCZ EBR Systems, Inc. $166.71M $0.37
APYX Apyx Medical Corp $171.26M $4.09
STEX Streamex Corp. $147.03M $1.41
INGN Inogen Inc $178.15M $6.58

News headlines (Yahoo Finance, 1h cache)

CVRx to Present at the William Blair 46th Annual Growth Stock Conference
2026-05-20 20:30 · Yahoo
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
2026-05-18 16:32 · Yahoo
Analysts Have Made A Financial Statement On CVRx, Inc.'s (NASDAQ:CVRX) First-Quarter Report
2026-05-15 10:39 · Yahoo
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
2026-05-14 12:00 · Yahoo
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)
2026-05-13 13:35 · Yahoo
CVRx Inc (CVRX) Q1 2026 Earnings Call Highlights: Strong U.S. Growth and Market Expansion Potential
2026-05-12 07:06 · Yahoo
CVRx Q1 Earnings Call Highlights
2026-05-11 23:05 · Yahoo
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates
2026-05-11 22:05 · Yahoo
CVRx Reports First Quarter 2026 Financial and Operating Results
2026-05-11 20:05 · Yahoo
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 21:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.